BHVN

AI Memo

Biohaven

As of 2026-09-20/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

BHV7000-303 pivotal focal-epilepsy readout • 2026-12-31

Base target: $14 / p=35% prob

Biggest risk

The partial hold introduces additional regulatory and development uncertainty shortly before the pivotal epilepsy readout. A prolonged hold or negative BHV7000-303 result would impair the principal near-term valuation driver, while early oncology data may be insufficient to offset that damage.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Resolution of the partial hold, a positive BHV7000-303 readout, and validating BHV-1530 data could restore confidence in opakalim while broadening pipeline value. BHV-1300 has also entered pivotal development in Graves' disease, providing a longer-duration source of optionality [#SEC-8K-2026-08-10].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-20

Base target

$14

p=35%

Bull target

$25

p=25%

Bear target

p=40%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FDA partial-hold resolution for opakalim
BHV-1530 Phase 1 update at ESMO
Resolution of the partial hold, a positive BHV7000-303 readout, and validating BHV-1530 data could restore confidence in opakalim while broadening pipeline value.

BearKey bullets

BHV-1530 remains an early Phase 1 oncology asset, so limited-patient activity signals may not translate into durable efficacy.
Biohaven is advancing several clinical programs simultaneously, increasing execution and portfolio-prioritization risk [#SEC-8K-2026-08-10].
Current cash-runway and post-event financing evidence is unavailable in the usable excerpts, limiting assessment of capital risk.

WatchKey bullets

BHV7000-303 pivotal focal-epilepsy readout

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $14 (p=35%)

Target spread vs base: +79% / -57%

Scenario probabilities

Bull Target: $25 (p=25%)Base Target: $14 (p=35%)Bear Target: $6 (p=40%)

Commentary

Recent coverage is sharply negative and concentrated on the FDA partial hold. The primary filing narrows the issue to new enrollment rather than ongoing dosing or the timing of the fully enrolled BHV7000-303 readout, but regulatory uncertainty remains material. The stock anchor is $13.62 as of September 18. Social, options, short-interest, employee, and post-event analyst-revision data are unavailable; their zero values represent missing evidence, not neutral readings. The deterministic prior remains negative across all supplied horizons, supporting a cautious monitoring stance.

As of 2026-09-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

FDA partial-hold resolution for opakalim
BHV-1530 Phase 1 update at ESMO

Scenarios

Bull Target (Scenario probability)

$25 / p=25% prob

Base Target (Scenario probability)

$14 / p=35% prob

Bear Target (Scenario probability)

$6 / p=40% prob

Analysis 2026-09-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
BHV7000-303 pivotal focal-epilepsy readout
The pivotal study is fully enrolled, and Biohaven maintained second-half 2026 topline timing despite the partial hold. With more than 600 randomized patients across the program continuing treatment, this is the principal binary test of opakalim's efficacy and tolerability thesis [#8-K-2026-09-10].
Prob 50.00% • Move 35.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

FDA partial-hold resolution for opakalim
2026-10-15
The FDA paused new enrollment in the BHV-7000 program pending additional nonclinical metabolite data, while dosing continues for already randomized patients. A satisfactory response could permit enrollment to resume; evidence of human relevance could prolong the hold [#8-K-2026-09-10].
Prob 45% • Move 15% • Priced-in 55%

Long-term Catalysts

Months to a year

BHV-1530 Phase 1 update at ESMO
2026-10-31
Biohaven plans to present updated Phase 1 data for its FGFR3-directed ADC at ESMO in October 2026, including reported signals of clinical activity in advanced solid tumors. Convincing data could diversify valuation support beyond epilepsy, although the program remains early-stage [#SEC-8K-2026-08-10].
Prob 45% • Move 14% • Priced-in 25%

Risks

BHV-1530 remains an early Phase 1 oncology asset, so limited-patient activity signals may not translate into durable efficacy.
Biohaven is advancing several clinical programs simultaneously, increasing execution and portfolio-prioritization risk [#SEC-8K-2026-08-10].
Current cash-runway and post-event financing evidence is unavailable in the usable excerpts, limiting assessment of capital risk.
The FDA partial hold on new BHV-7000 enrollment may persist if the requested metabolite work raises human-safety concerns [#8-K-2026-09-10].
The fully enrolled BHV7000-303 study is a high-impact binary event; an efficacy or tolerability disappointment could materially reduce opakalim's value.

Peers

Symbol	Summary
HRMY	Harmony Biosciences is the closest supplied neuroscience comparator, but its commercial-stage profile differs materially from Biohaven's clinical-stage and binary-readout exposure. It is useful for therapeutic-area context rather than direct valuation.
HCM	HUTCHMED has a similar market capitalization, but its oncology-focused portfolio and commercialization profile make it a loose valuation comparator rather than a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-20

Loading AI feed…

Symbol

Summary

HRMY

Harmony Biosciences is the closest supplied neuroscience comparator, but its commercial-stage profile differs materially from Biohaven's clinical-stage and binary-readout exposure. It is useful for therapeutic-area context rather than direct valuation.

HCM

HUTCHMED has a similar market capitalization, but its oncology-focused portfolio and commercialization profile make it a loose valuation comparator rather than a direct operating peer.